RT @CCR_AACR: Clinical Trial in the April 15 issue!: AMG 337 Phase 2 Study in MET-Amplified Tumors. https://t.co/YzNBBvWQ68 https://t.co/92…
RT @CCR_AACR: Clinical Trial in the April 15 issue!: AMG 337 Phase 2 Study in MET-Amplified Tumors. https://t.co/YzNBBvWQ68 https://t.co/92…
RT @CCR_AACR: Clinical Trial in the April 15 issue!: AMG 337 Phase 2 Study in MET-Amplified Tumors. https://t.co/YzNBBvWQ68 https://t.co/92…
Clinical Trial in the April 15 issue!: AMG 337 Phase 2 Study in MET-Amplified Tumors. https://t.co/YzNBBvWQ68 https://t.co/92kR4NLeDW
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors https://t.co/0CJTSZs047
A Multicenter Phase 2 Study of AMG 337 in Patients With MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other Solid Tumors https://t.co/zXW4hVZGc9